Evogen said the US Patent and Trademark Office (USPTO) issued a patent covering the company’s biomarker-based blood test that can accurately identify epileptic seizures.
The patent is owned by the University of Pennsylvania and is exclusively licensed to Evogen.
Evogen CEO Todd Wallach said: “This patent validates the key concepts and claims underlying our scientific approach and is the first of what we anticipate will be a series of patents in the U.S., Europe and other major territories for our biomarker-based technology and products.
“We believe that our EvoScoreDX biomarker-based blood test has the potential to revolutionize the diagnosis of epilepsy, which currently lacks objective, timely and cost effective diagnostic tools.
“We intend to pursue an active intellectual property strategy in partnership with Penn and with our own novel and proprietary core technologies, seeking broad patent protection for our current and future neurological assays.”
Dora Mitchell, director of the UPstart program at PCI Ventures, a division of the Penn Center for Innovation at the University of Pennsylvania, said: “The University of Pennsylvania is committed to working with industry innovators such as Evogen to commercialize the discoveries of our world-class researchers.
“We are pleased that this first patent for our seizure biomarker technology has issued and look forward to working with Evogen to expand the intellectual property protection for this novel approach that could help improve the diagnosis and treatment of seizures.”
Evogen’s biomarker technology was invented and developed by Dr. Peter Crino and his colleague Dr. John Pollard at the Perelman School of Medicine at Penn.
Dr. Crino said: “We undertook the research that resulted in this patent because diagnosing epilepsy has too often been difficult, costly and imprecise.
“Issuance of this patent supports the development and commercialization of this innovative biomarker-based approach that can benefit epilepsy patients, reduce misdiagnoses and facilitate clinical trials.”